Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $86.59 Analyst target: $163.58 Upside: 88.91%
Abivax SA is a clinical-stage biotechnology firm focused on pioneering immunotherapies for chronic inflammatory diseases and viral infections. Its lead candidate, ABX464, is in advanced clinical trials targeting ulcerative colitis, utilizing a novel approach that integrates antibody-mediated therapies with proprietary compounds. Backed by a robust pipeline and an experienced scientific team, Abivax is strategically positioned to meet substantial unmet medical needs, making it an attractive prospect for institutional investors aiming to engage with the growing immunotherapy landscape.
See the full interactive analysis & chart →Informational only — not investment advice.